{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T02:54:12Z","timestamp":1790045652374,"version":"4.0.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2007,10,1]],"date-time":"2007-10-01T00:00:00Z","timestamp":1191196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuroscience Letters"],"published-print":{"date-parts":[[2007,10]]},"DOI":"10.1016\/j.neulet.2007.08.031","type":"journal-article","created":{"date-parts":[[2007,8,20]],"date-time":"2007-08-20T12:45:21Z","timestamp":1187613921000},"page":"167-172","source":"Crossref","is-referenced-by-count":14,"title":["IGF-1 exacerbates the neurotoxicity of the mitochondrial inhibitor 3NP in rats"],"prefix":"10.1016","volume":"425","author":[{"given":"Carole","family":"Escartin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Boyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis-Pierre","family":"Bemelmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Hantraye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Brouillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neulet.2007.08.031_bib1","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.neuron.2005.06.005","article-title":"p53 mediates cellular dysfunction and behavioral abnormalities in Huntington's disease","volume":"47","author":"Bae","year":"2005","journal-title":"Neuron"},{"key":"10.1016\/j.neulet.2007.08.031_bib2","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.nbd.2004.09.017","article-title":"Minocycline in phenotypic models of Huntington's disease","volume":"18","author":"Bantubungi","year":"2005","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neulet.2007.08.031_bib3","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0166-2236(00)01584-8","article-title":"Energetics in the pathogenesis of neurodegenerative diseases","volume":"23","author":"Beal","year":"2000","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neulet.2007.08.031_bib4","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1091\/mbc.E05-07-0607","article-title":"Involvement of mitochondrial complex II defects in neuronal death produced by N-terminus fragment of mutated huntingtin","volume":"17","author":"Benchoua","year":"2006","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.neulet.2007.08.031_bib5","doi-asserted-by":"crossref","first-page":"5020","DOI":"10.1523\/JNEUROSCI.23-12-05020.2003","article-title":"Calpain is a major cell death effector in selective striatal degeneration induced in vivo by 3-nitropropionate: implications for Huntington's disease","volume":"23","author":"Bizat","year":"2003","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neulet.2007.08.031_bib6","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0301-0082(99)00005-2","article-title":"Replicating Huntington's disease phenotype in experimental animals","volume":"59","author":"Brouillet","year":"1999","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.neulet.2007.08.031_bib7","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1111\/j.1471-4159.2005.03515.x","article-title":"3-Nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease","volume":"95","author":"Brouillet","year":"2005","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neulet.2007.08.031_bib8","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S0142-9612(03)00562-3","article-title":"Microspheres containing insulin-like growth factor I for treatment of chronic neurodegeneration","volume":"25","author":"Carrascosa","year":"2004","journal-title":"Biomaterials"},{"key":"10.1016\/j.neulet.2007.08.031_bib9","doi-asserted-by":"crossref","first-page":"5678","DOI":"10.1523\/JNEUROSCI.21-15-05678.2001","article-title":"Circulating insulin-like growth factor I mediates the protective effects of physical exercise against brain insults of different etiology and anatomy","volume":"21","author":"Carro","year":"2001","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neulet.2007.08.031_bib10","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1038\/nm1202-793","article-title":"Serum insulin-like growth factor I regulates brain amyloid-beta levels","volume":"8","author":"Carro","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.neulet.2007.08.031_bib11","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1385\/MN:27:2:153","article-title":"Brain repair and neuroprotection by serum insulin-like growth factor I","volume":"27","author":"Carro","year":"2003","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neulet.2007.08.031_bib12","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1097\/00001756-200410050-00022","article-title":"Insulin growth factor-1 protects against excitotoxicity in the rat striatum","volume":"15","author":"Escartin","year":"2004","journal-title":"Neuroreport"},{"key":"10.1016\/j.neulet.2007.08.031_bib13","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1399-0004.1985.tb00185.x","article-title":"Diabetes mellitus in Huntington disease","volume":"27","author":"Farrer","year":"1985","journal-title":"Clin. Genet."},{"key":"10.1016\/j.neulet.2007.08.031_bib14","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1046\/j.1471-4159.1995.64010430.x","article-title":"Characterization of the excitotoxic potential of the reversible succinate dehydrogenase inhibitor malonate","volume":"64","author":"Greene","year":"1995","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neulet.2007.08.031_bib15","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/j.1432-1033.1990.tb15595.x","article-title":"Insulin-like growth factors I and II","volume":"190","author":"Humbel","year":"1990","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.neulet.2007.08.031_bib16","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S1534-5807(02)00188-0","article-title":"The IGF-1\/Akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by Akt","volume":"2","author":"Humbert","year":"2002","journal-title":"Dev. Cell"},{"key":"10.1016\/j.neulet.2007.08.031_bib17","series-title":"Neuronal Death by Accident or by Design","first-page":"137","article-title":"Neuronal death in Huntington's disease: multiple pathways for one issue?","author":"Humbert","year":"2001"},{"key":"10.1016\/j.neulet.2007.08.031_bib18","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2337\/diabetes.48.3.649","article-title":"Mice transgenic for an expanded CAG repeat in the Huntington's disease gene develop diabetes","volume":"48","author":"Hurlbert","year":"1999","journal-title":"Diabetes"},{"key":"10.1016\/j.neulet.2007.08.031_bib19","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1096\/fj.05-5085fje","article-title":"Brain mitochondrial defects amplify intracellular [Ca2+] rise and neurodegeneration but not Ca2+ entry during NMDA receptor activation","volume":"20","author":"Jacquard","year":"2006","journal-title":"FASEB J."},{"key":"10.1016\/j.neulet.2007.08.031_bib20","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1126\/science.1086137","article-title":"Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model","volume":"301","author":"Kaspar","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.neulet.2007.08.031_bib21","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0022-510X(01)00532-9","article-title":"Intranasal administration of insulin-like growth factor-I bypasses the blood\u2013brain barrier and protects against focal cerebral ischemic damage","volume":"187","author":"Liu","year":"2001","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.neulet.2007.08.031_bib22","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1523\/JNEUROSCI.18-01-00156.1998","article-title":"Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease","volume":"18","author":"Matthews","year":"1998","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neulet.2007.08.031_bib23","doi-asserted-by":"crossref","first-page":"4478","DOI":"10.1523\/JNEUROSCI.22-11-04478.2002","article-title":"Corticostriatopallidal neuroprotection by adenovirus-mediated ciliary neurotrophic factor gene transfer in a rat model of progressive striatal degeneration","volume":"22","author":"Mittoux","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neulet.2007.08.031_bib24","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1006\/exnr.1997.6520","article-title":"Riluzole reduces incidence of abnormal movements but not striatal cell death in a primate model of progressive striatal degeneration","volume":"146","author":"Palfi","year":"1997","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neulet.2007.08.031_bib25","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/nn884","article-title":"Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines","volume":"5","author":"Panov","year":"2002","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neulet.2007.08.031_bib26","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1530\/eje.0.1490377","article-title":"Central effects of the somatotropic system","volume":"149","author":"Schneider","year":"2003","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.neulet.2007.08.031_bib27","unstructured":"The Huntington study group, A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group, Cell, 72 (1993) pp. 971\u2013983."},{"key":"10.1016\/j.neulet.2007.08.031_bib28","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S0140-6736(04)16739-1","article-title":"Targeting energy metabolism in Huntington's disease","volume":"364","author":"Walker","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.neulet.2007.08.031_bib29","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s00467-004-1602-1","article-title":"Molecular physiology, pathology, and regulation of the growth hormone\/insulin-like growth factor-I system","volume":"20","author":"Woelfle","year":"2005","journal-title":"Pediatr. Nephrol."}],"container-title":["Neuroscience Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030439400700883X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030439400700883X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,2]],"date-time":"2019-05-02T08:56:01Z","timestamp":1556787361000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030439400700883X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,10]]}},"alternative-id":["S030439400700883X"],"URL":"https:\/\/doi.org\/10.1016\/j.neulet.2007.08.031","relation":{},"ISSN":["0304-3940"],"issn-type":[{"value":"0304-3940","type":"print"}],"subject":[],"published":{"date-parts":[[2007,10]]}}}